Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Adaptation of Cells to Serum-Free Media – V 2.0

Posted on By


Biosimilars: SOP for Adaptation of Cells to Serum-Free Media – V 2.0


Standard Operating Procedure for Adaptation of Cells to Serum-Free Media in Biosimilar Development

Department Biosimilars
SOP No. SOP/BS/016/2025
Supersedes SOP/BS/016/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To describe the step-by-step procedure for adapting mammalian cell lines used in biosimilar production from serum-containing media to serum-free media to support regulatory compliance, scalability, and safety.

2. Scope

This SOP applies to all R&D and process development personnel involved in upstream cell culture operations for biosimilars where serum-free media is required for clone expansion or bioreactor inoculation.

3. Responsibilities

  • Cell Culture Scientist: Designs and monitors the adaptation process.
  • Technician: Performs daily cell culture maintenance and media exchanges.
  • QA Officer: Reviews adaptation logs and confirms compliance with procedural requirements.
See also  Biosimilars: SOP for Selection of Stably Transfected Clones - V 2.0

4. Accountability

The Head of Upstream Process Development is accountable for ensuring successful adaptation of production clones to serum-free conditions and maintaining traceable documentation.

5. Procedure

5.1 Preparation and Planning

  1. Select serum-free medium compatible with the specific cell line (e.g., CD-CHO, ProCHO5).
  2. Prepare complete serum-containing medium and serum-free medium (SFM) in advance.
  3. Seed cells at 3–5 × 105 cells/mL in serum-containing medium in T-75 flasks.

5.2 Stepwise Adaptation Schedule

  1. Begin with a 75:25 mixture of serum-containing medium to SFM.
  2. Allow cells to reach ~80% confluency or 1 × 106 cells/mL.
  3. Subculture using the next ratio: 50:50, then 25:75, and finally 100% SFM in successive passages.
  4. Monitor cell viability, morphology, and doubling time after each adaptation step.
  5. If viability drops below 85%, repeat the previous step before advancing.
See also  Biosimilars: SOP for Transient Transfection Methods - V 2.0

5.3 Maintenance in Serum-Free Medium

  1. Once cells grow stably in 100% SFM for at least 3 passages, consider adaptation complete.
  2. Expand adapted cells for productivity testing and bioreactor inoculum.
  3. Document final adaptation status in the Adaptation Completion Log (Annexure-2).

5.4 Troubleshooting

  1. For poor growth or clumping, supplement with minimal FBS (≤1%) for one cycle.
  2. Increase passage interval or seeding density if doubling time is extended.
  3. Ensure media components (e.g., L-glutamine) are not degraded during storage.

6. Abbreviations

  • SFM: Serum-Free Medium
  • FBS: Fetal Bovine Serum
  • QA: Quality Assurance
  • CHO: Chinese Hamster Ovary cells

7. Documents

  1. Adaptation Tracking Log (Annexure-1)
  2. Adaptation Completion Log (Annexure-2)

8. References

  • ICH Q5D – Cell Substrate Guidelines
  • WHO TRS 978 – Guidelines for Serum-Free Media
  • CDSCO Guidelines on Animal-Origin-Free Cell Culture Systems
See also  Biosimilars: SOP for mRNA Transcript Analysis (RT-PCR) - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Adaptation Tracking Log

Date Passage No. Medium Ratio Viability (%) Cell Density Remarks
01/05/2025 P1 75:25 92 5.1 × 10⁵/mL Normal growth
03/05/2025 P2 50:50 89 6.3 × 10⁵/mL Slight lag

Annexure-2: Adaptation Completion Log

Clone ID Media Used Completion Date Stable Passage No. Adapted By Remarks
CL-BS-016 CD-CHO 04/05/2025 P6 Sunita Reddy Fully adapted

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Incorporated adaptation log format and troubleshooting section Annual SOP review
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: BA-BE Studies: SOP for Blood Sample Collection Schedule Adherence – V 2.0
Next Post: Creams: SOP for Handling and Storage of Machine Parts – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version